Abstract:Abstract Forkhead box protein M1 (FOXM1) is often overexpressed in human cancers and strongly associated with therapy resistance and less good patient survival. The chemotherapy options for patients with the most aggressive types of solid cancers remain very limited because of the acquired drug resistance, making the therapy less effective. NPM1 mutation through the inactivation of FOXM1 via FOXM1 relocalization to the cytoplasm confers more favorable treatment outcomes for AML patients, confirming FOXM1 as a crucial target to overcome drug resistance. Pharmacological inhibition of FOXM1 could be a promising approach to sensitize therapy-resistant cancers. Here, we explore a novel FOXM1 inhibitor STL001, a first-generation modification drug of our previously reported FOXM1 inhibitor STL427944. STL001 preserves the mode of action of the STL427944; however, STL001 is up to 50 times more efficient in reducing FOXM1 activity in a variety of solid cancers. The most conventional cancer therapies studied here induce FOXM1 overexpression in solid cancers. The therapy-induced FOXM1 overexpression may explain the failure or reduced efficacy of these drugs in cancer patients. Interestingly, STL001 increased the sensitivity of cancer cells to conventional cancer therapies by suppressing both the high-endogenous and drug-induced FOXM1. Notably, STL001 does not provide further sensitization to FOXM1-KD cancer cells, suggesting that the sensitization effect is conveyed specifically through FOXM1 suppression. RNA-seq and gene set enrichment studies revealed prominent suppression of FOXM1-dependent pathways and gene ontologies. Also, gene regulation by STL001 showed extensive overlap with FOXM1-KD, suggesting a high selectivity of STL001 toward the FOXM1 regulatory network. A completely new activity of FOXM1, mediated through steroid/cholesterol biosynthetic process and protein secretion in cancer cells was also detected. Collectively, STL001 offers intriguing translational opportunities as combination therapies targeting FOXM1 activity in a variety of human cancers driven by FOXM1.

FOXM1: a potential therapeutic target in human solid cancers

FOXN Transcription Factors: Regulation and Significant Role in Cancer

FoxM1 as a novel therapeutic target for cancer drug therapy.

FOXN Transcription Factors: Regulation and Significant Role in Cancer.

Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer

FOXO Signaling Pathways as Therapeutic Targets in Cancer

Transcription factor FoxM1-A novel target for cancer therapy

Research Progress in the Relationship Between FOXM1 and Neoplasm Metabolism

FOXO and FOXM1 in Cancer: the FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy.

FOXM1: From cancer initiation to progression and treatment.

Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies

Molecular and Cellular Pathobiology FoxO Transcription Factors Promote AKT Ser 473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI 3 K – AKT Pathway

FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer

Supplementary Methods and Figures Legends from FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway

The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance

Retraction Note To: FoxM1 Down-Regulation Leads to Inhibition of Proliferation, Migration and Invasion of Breast Cancer Cells Through the Modulation of Extra-Cellular Matrix Degrading Factors

The Promise of Combination Therapies with FOXM1 Inhibitors for Cancer Treatment

Therapeutic Landscape of FOXM1 in Triple-Negative Breast Cancer and Aggressive Solid Cancers

FOXM1 and Its Oncogenic Signaling in Pancreatic Cancer Pathogenesis.

FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis

A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics